Wilhelmus Cm Groenhuysen Novo Cure LTD (NVCR) insider trading activity

Wilhelmus Cm Groenhuysen is Chief Operating Officer of NovoCure Ltd. Currently has a direct ownership of 252,290 shares of NVCR, which is worth approximately $7.75 Million. The most recent transaction as insider was on Jun 28, 2024, when has been sold 1,055 shares (Ordinary Shares) at a price of $12.24 per share, resulting in proceeds of $12,913. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 252K

0% 3M change

20.24% 12M change

Total Value Held $7.75 Million

WILHELMUS CM GROENHUYSEN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 28 2024	BUY Grant, award, or other acquisition	$12,913 $12.24 p/Share	1,055 Added 0.42%	252,290 Ordinary Shares
Mar 04 2024	SELL Open market or private sale	$19,484 $16.01 p/Share	1,217 Reduced 0.48%	251,235 Ordinary Shares
Mar 01 2024	SELL Open market or private sale	$33,775 $16.03 p/Share	2,107 Reduced 0.83%	252,452 Ordinary Shares
Feb 28 2024	SELL Open market or private sale	$37,170 $16.14 p/Share	2,303 Reduced 0.9%	254,559 Ordinary Shares
Feb 27 2024	BUY Grant, award, or other acquisition	$766,654 $16.3 p/Share	47,034 Added 15.48%	256,862 Ordinary Shares
Dec 31 2023	BUY Grant, award, or other acquisition	$38 $12.69 p/Share	3 Added 0.0%	209,828 Ordinary Shares
Sep 01 2023	SELL Open market or private sale	$6,415 $21.82 p/Share	294 Reduced 0.14%	209,825 Ordinary Shares
Jun 30 2023	BUY Grant, award, or other acquisition	$12,912 $35.28 p/Share	366 Added 0.17%	210,119 Ordinary Shares
Mar 03 2023	SELL Open market or private sale	$1,952,361 $76.16 p/Share	25,635 Reduced 10.89%	209,753 Ordinary Shares
Mar 03 2023	BUY Grant, award, or other acquisition	-	51,986 Added 18.09%	235,388 Ordinary Shares
Mar 02 2023	SELL Open market or private sale	$91,314 $75.28 p/Share	1,213 Reduced 0.66%	183,402 Ordinary Shares
Mar 01 2023	SELL Open market or private sale	$165,243 $76.36 p/Share	2,164 Reduced 1.16%	184,615 Ordinary Shares
Feb 28 2023	BUY Grant, award, or other acquisition	-	21,653 Added 10.39%	186,779 Ordinary Shares
Jan 06 2023	BUY Grant, award, or other acquisition	$6,354 $62.3 p/Share	102 Added 0.06%	165,126 Ordinary Shares
Sep 02 2022	SELL Open market or private sale	$23,396 $79.04 p/Share	296 Reduced 0.18%	165,024 Ordinary Shares
Jul 05 2022	BUY Grant, award, or other acquisition	$12,879 $59.08 p/Share	218 Added 0.13%	165,320 Ordinary Shares
Mar 08 2022	SELL Open market or private sale	$204,902 $70.1 p/Share	2,923 Reduced 1.74%	165,102 Ordinary Shares
Mar 04 2022	SELL Open market or private sale	$180,883 $70.41 p/Share	2,569 Reduced 1.51%	168,025 Ordinary Shares
Mar 03 2022	SELL Open market or private sale	$96,924 $74.5 p/Share	1,301 Reduced 0.76%	170,594 Ordinary Shares
Mar 03 2022	BUY Grant, award, or other acquisition	-	21,921 Added 11.31%	171,895 Ordinary Shares
Jan 06 2022	BUY Grant, award, or other acquisition	$4,786 $63.82 p/Share	75 Added 0.05%	149,974 Ordinary Shares
Sep 02 2021	SELL Open market or private sale	$25,020 $138.23 p/Share	181 Reduced 0.12%	149,899 Ordinary Shares
Jul 06 2021	BUY Grant, award, or other acquisition	$9,050 $137.12 p/Share	66 Added 0.04%	150,080 Ordinary Shares
Mar 08 2021	SELL Open market or private sale	$392,953 $130.81 p/Share	3,004 Reduced 1.92%	153,684 Restricted Share Units
Mar 04 2021	SELL Open market or private sale	$530,118 $137.55 p/Share	3,854 Reduced 2.4%	156,688 Restricted Share Units

Also insider at

OPTN

OptiNose, Inc. Healthcare

Director

WCG